9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      27-Hydroxycholesterol impairs neuronal glucose uptake through an IRAP/GLUT4 system dysregulation

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Ismail et al. show that 27-hydroxycholesterol, a peripheral cholesterol metabolite capable of passing the blood–brain barrier, reduces brain glucose uptake by upregulating the renin-angiotensin system and inhibiting GLUT4. This alteration affects memory processes and is likely to have implications on neurodegenerative diseases.

          Abstract

          Hypercholesterolemia is associated with cognitively deteriorated states. Here, we show that excess 27-hydroxycholesterol (27-OH), a cholesterol metabolite passing from the circulation into the brain, reduced in vivo brain glucose uptake, GLUT4 expression, and spatial memory. Furthermore, patients exhibiting higher 27-OH levels had reduced 18F-fluorodeoxyglucose uptake. This interplay between 27-OH and glucose uptake revealed the engagement of the insulin-regulated aminopeptidase (IRAP). 27-OH increased the levels and activity of IRAP, countered the IRAP antagonist angiotensin IV (AngIV)–mediated glucose uptake, and enhanced the levels of the AngIV-degrading enzyme aminopeptidase N (AP-N). These effects were mediated by liver X receptors. Our results reveal a molecular link between cholesterol, brain glucose, and the brain renin-angiotensin system, all of which are affected in some neurodegenerative diseases. Thus, reducing 27-OH levels or inhibiting AP-N maybe a useful strategy in the prevention of the altered glucose metabolism and memory decline in these disorders.

          Related collections

          Most cited references42

          • Record: found
          • Abstract: found
          • Article: not found

          Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry.

          A method based on isotope dilution-mass spectrometry was developed for the determination of nine cholesterol oxidation products in human plasma. The cholesterol oxidation products determined were cholest-5-ene-3 beta,7 alpha-diol, cholest-5-ene-3 beta,7 beta-diol (7 alpha- and 7 beta-hydroxycholesterol, respectively), 3 beta-hydroxycholest-5-en-7-one(7-oxocholesterol),5,6 alpha-epoxy-5 alpha- cholestan-3 beta-ol (cholesterol-5 alpha,6 alpha-epoxide),5,6 beta-epoxy-5 beta-cholestan-3 beta-ol (cholesterol-5 beta,6 beta-epoxide), (cholesterol-5 beta,6 beta-epoxide), cholestane-3 beta,5 alpha,6 beta-triol, cholest-5-ene-3 beta,24-diol (24-hydroxycholesterol), cholest-5-ene-3 beta,25-diol (25-hydroxycholesterol), and cholest-5-ene-3 beta,27-diol (27-hydroxycholesterol). A corresponding deuterium-labeled internal standard, containing 3 to 6 deuterium atoms, was synthesized for each cholesterol oxidation product except 5 beta,6 beta-epoxycholesterol which was determined using the internal standard for 5 alpha,6 alpha-epoxycholesterol. Plasma from 31 healthy volunteers was analyzed by the new method and 27-, 24-, and 7 alpha-hydroxycholesterol were the most abundant cholesterol oxidation products (mean values 154, 64, and 43 ng/ml, respectively). The other oxysterols determined were present in concentrations lower than 30 ng/ml. Males had higher 27-hydroxycholesterol concentrations in plasma than females. The 5,6-oxygenated products were present mainly unesterified while the other oxidation products were mostly in esterified form.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Glucose transporter expression in the central nervous system: relationship to synaptic function.

            The family of facilitative glucose transporter (GLUT) proteins is responsible for the entry of glucose into cells throughout the periphery and the brain. The expression, regulation and activity of GLUTs play an essential role in neuronal homeostasis, since glucose represents the primary energy source for the brain. Brain GLUTs exhibit both cell type and region specific localizations suggesting that the transport of glucose across the blood-brain barrier is tightly regulated and compartmentalized. As seen in the periphery, insulin-sensitive GLUTs are expressed in the brain and therefore may participate in the central actions of insulin. The aim of this review will be to discuss the localization of GLUTs expressed in the central nervous system (CNS), with a special emphasis upon the recently identified GLUT isoforms. In addition, we will discuss the regulation, activity and insulin-stimulated trafficking of GLUTs in the CNS, especially in relation to the centrally mediated actions of insulin and glucose.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              HDL and cognition in neurodegenerative disorders.

              High-density lipoproteins (HDLs) are a heterogeneous group of lipoproteins composed of various lipids and proteins. HDL is formed both in the systemic circulation and in the brain. In addition to being a crucial player in the reverse cholesterol transport pathway, HDL possesses a wide range of other functions including anti-oxidation, anti-inflammation, pro-endothelial function, anti-thrombosis, and modulation of immune function. It has been firmly established that high plasma levels of HDL protect against cardiovascular disease. Accumulating evidence indicates that the beneficial role of HDL extends to many other systems including the central nervous system. Cognition is a complex brain function that includes all aspects of perception, thought, and memory. Cognitive function often declines during aging and this decline manifests as cognitive impairment/dementia in age-related and progressive neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. A growing concern is that no effective therapy is currently available to prevent or treat these devastating diseases. Emerging evidence suggests that HDL may play a pivotal role in preserving cognitive function under normal and pathological conditions. This review attempts to summarize recent genetic, clinical and experimental evidence for the impact of HDL on cognition in aging and in neurodegenerative disorders as well as the potential of HDL-enhancing approaches to improve cognitive function.
                Bookmark

                Author and article information

                Journal
                J Exp Med
                J. Exp. Med
                jem
                jem
                The Journal of Experimental Medicine
                The Rockefeller University Press
                0022-1007
                1540-9538
                6 March 2017
                : 214
                : 3
                : 699-717
                Affiliations
                [1 ]Division of Neurogeriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, 141 86 Stockholm, Sweden
                [2 ]Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, 141 86 Stockholm, Sweden
                [3 ]Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden
                [4 ]Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska University Hospital, 141 86 Huddinge, Sweden
                [5 ]Department of Radiology, Karolinska University Hospital, 141 86 Huddinge, Sweden
                [6 ]Center for Research, Prevention, and Treatment of Atherosclerosis, Hadassah Hebrew University Medical Center, Jerusalem 91120, Israel
                Author notes
                Correspondence to Angel Cedazo-Mínguez: Angel.Cedazo-Mínguez@ 123456ki.se
                [*]

                M.-A.-M. Ismail and L. Mateos contributed equally to this paper.

                Author information
                http://orcid.org/0000-0001-7320-1004
                http://orcid.org/0000-0002-1842-9476
                http://orcid.org/0000-0003-0008-5641
                http://orcid.org/0000-0002-3115-2977
                http://orcid.org/0000-0001-8740-9068
                http://orcid.org/0000-0002-9905-8426
                http://orcid.org/0000-0001-6087-9190
                http://orcid.org/0000-0003-4626-4864
                Article
                20160534
                10.1084/jem.20160534
                5339669
                28213512
                93fadf63-b975-4a8f-97de-89c7d03c9f5f
                © 2017 Ismail et al.

                This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

                History
                : 14 April 2016
                : 17 August 2016
                : 28 October 2016
                Funding
                Funded by: Swedish Brain Power, DOI https://doi.org/10.13039/501100007416;
                Funded by: Stockholm County Council, DOI https://doi.org/10.13039/501100004348;
                Funded by: Karolinska Institutet, DOI https://doi.org/10.13039/501100004047;
                Funded by: Stiftelse Olle Engkvist Byggmästare, DOI https://doi.org/10.13039/501100004200;
                Funded by: Gun och Bertil Stohnes Stiftelse, DOI https://doi.org/10.0.50.239/100009673;
                Funded by: Stiftelsen Gamla Tjänarinnor, DOI https://doi.org/10.13039/100010815;
                Funded by: Hjärnfonden, DOI https://doi.org/10.13039/501100003792;
                Funded by: Alzheimerfonden, DOI https://doi.org/10.13039/501100008599;
                Categories
                Research Articles
                Article
                321
                320

                Medicine
                Medicine

                Comments

                Comment on this article